The pleiotropy associated with de novo variants in CHD4, CNOT3, and SETD5 extends to moyamoya angiopathy

Article metrics

Abstract

Purpose

Moyamoya angiopathy (MMA) is a cerebrovascular disease characterized by occlusion of large arteries, which leads to strokes starting in childhood. Twelve altered genes predispose to MMA but the majority of cases of European descent do not have an identified genetic trigger.

Methods

Exome sequencing from 39 trios were analyzed.

Results

We identified four de novo variants in three genes not previously associated with MMA: CHD4, CNOT3, and SETD5. Identification of additional rare variants in these genes in 158 unrelated MMA probands provided further support that rare pathogenic variants in CHD4 and CNOT3 predispose to MMA. Previous studies identified de novo variants in these genes in children with developmental disorders (DD), intellectual disability, and congenital heart disease.

Conclusion

These genes encode proteins involved in chromatin remodeling, and taken together with previously reported genes leading to MMA-like cerebrovascular occlusive disease (YY1AP1, SMARCAL1), implicate disrupted chromatin remodeling as a molecular pathway predisposing to early onset, large artery occlusive cerebrovascular disease. Furthermore, these data expand the spectrum of phenotypic pleiotropy due to alterations of CHD4, CNOT3, and SETD5 beyond DD to later onset disease in the cerebrovascular arteries and emphasize the need to assess clinical complications into adulthood for genes associated with DD.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1

References

  1. 1.

    Masuda J, Ogata J, Yutani C. Smooth-muscle cell-proliferation and localization of macrophages and T-cells in the occlusive intracranial major arteries in moyamoya disease. Stroke. 1993;24:1960–1967.

  2. 2.

    Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009;360:1226–1237.

  3. 3.

    Kamada F, Aoki Y, Narisawa A, et al. A genome-wide association study identifies RNF213 as the first moyamoya disease gene. J Hum Genet. 2011;56:34–40.

  4. 4.

    Friedman JM, Arbiser J, Epstein JA, et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med. 2002;4:105–111.

  5. 5.

    Rocha R, Soro I, Leitao A, Silva ML, Leao M. Moyamoya vascular pattern in Alagille syndrome. Pediatr Neurol. 2012;47:125–128.

  6. 6.

    Miskinyte S, Butler MG, Herve D, et al. Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya. Am J Hum Genet. 2011;88:718–728.

  7. 7.

    Herve D, Philippi A, Belbouab R, et al. Loss of alpha1beta1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia. Am J Hum Genet. 2014;94:385–394.

  8. 8.

    Bober MB, Khan N, Kaplan J, et al. Majewski osteodysplastic primordial dwarfism type II (MOPD II): expanding the vascular phenotype. Am J Med Genet A. 2010;152A:960–965.

  9. 9.

    Milewicz DM, Ostergaard JR, la-Kokko LM, et al. De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am J Med Genet A. 2010;152A:2437–2443.

  10. 10.

    Guo DC, Duan XY, Regalado ES, et al. Loss-of-function mutations in YY1AP1 lead to Grange syndrome and a fibromuscular dysplasia-like vascular disease. Am J Hum Genet. 2017;100:21–30.

  11. 11.

    Weiss K, Terhal PA, Cohen L, et al. De novo mutations in CHD4, an ATP-dependent chromatin remodeler gene, cause an intellectual disability syndrome with distinctive dysmorphisms. Am J Hum Genet. 2016;99:934–941.

  12. 12.

    Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. Nature. 2017;542:433–438.

  13. 13.

    Powis Z, Farwell Hagman KD, Mroske C, et al. Expansion and further delineation of the SETD5 phenotype leading to global developmental delay, variable dysmorphic features, and reduced penetrance. Clin Genet. 2018;93:752–761.

  14. 14.

    Sillibourne JE, Delaval B, Redick S, Sinha M, Doxsey SJ. Chromatin remodeling proteins interact with pericentrin to regulate centrosome integrity. Mol Biol Cell. 2007;18:3667–3680.

  15. 15.

    Nitarska J, Smith JG, Sherlock WT, et al. A functional switch of NuRD chromatin remodeling complex subunits regulates mouse cortical development. Cell Rep. 2016;17:1683–1698.

  16. 16.

    Yamaguchi T, Suzuki T, Sato T, et al. The CCR4-NOT deadenylase complex controls Atg7-dependent cell death and heart function. Sci Signal. 2018;11:eaan3638.

  17. 17.

    Peng W, Togawa C, Zhang K, Kurdistani SK. Regulators of cellular levels of histone acetylation in Saccharomyces cerevisiae. Genetics. 2008;179:277–289.

  18. 18.

    Neely GG, Kuba K, Cammarato A, et al. A global in vivo Drosophila RNAi screen identifies NOT3 as a conserved regulator of heart function. Cell. 2010;141:142–153.

  19. 19.

    Osipovich AB, Gangula R, Vianna PG, Magnuson MA. Setd5 is essential for mammalian development and the co-transcriptional regulation of histone acetylation. Development. 2016;143:4595–4607.

  20. 20.

    Villain G, Poissonnier L, Noueihed B, et al. miR-126-5p promotes retinal endothelial cell survival through SetD5 regulation in neurons. Development. 2018;145:dev156232.

Download references

Acknowledgements

We are grateful to the patients and their family members for participating in this study. This study was funded by the Henrietta B. and Frederick H. Bugher Foundation (D.M.M.), the Texas Heart Institute Fibromuscular Dysplasia Project (D.M.M.), INSERM (E.T.-L.), the American Heart Association (18POST34020031; A. P.) and the Fondation pour le Recherche Médicale (S.G.). Exome sequencing was funded by the National Human Genome Research Institute and the National Heart, Lung, and Blood Institute grant HG006493 to D.A.N., M.J.B., and Suzanne Leal. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author information

Correspondence to Dianna M. Milewicz MD, PhD.

Ethics declarations

Disclosure

The authors declare no conflicts of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pinard, A., Guey, S., Guo, D. et al. The pleiotropy associated with de novo variants in CHD4, CNOT3, and SETD5 extends to moyamoya angiopathy. Genet Med (2019) doi:10.1038/s41436-019-0639-2

Download citation

Keywords

  • moyamoya angiopathy
  • exome sequencing
  • developmental disorders
  • chromatin remodeling